314 related articles for article (PubMed ID: 31606087)
21. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
[TBL] [Abstract][Full Text] [Related]
22. Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.
Linciano P; Pinzi L; Belluti S; Chianese U; Benedetti R; Moi D; Altucci L; Franchini S; Imbriano C; Sorbi C; Rastelli G
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2080-2086. PubMed ID: 34583596
[TBL] [Abstract][Full Text] [Related]
23. Expression and Crystallization of HDAC6 Tandem Catalytic Domains.
Langousis G; Sanchez J; Kempf G; Matthias P
Methods Mol Biol; 2023; 2589():467-480. PubMed ID: 36255643
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
25. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
Kurohara T; Tanaka K; Takahashi D; Ueda S; Yamashita Y; Takada Y; Takeshima H; Yu S; Itoh Y; Hase K; Suzuki T
Chembiochem; 2021 Nov; 22(22):3158-3163. PubMed ID: 34224197
[TBL] [Abstract][Full Text] [Related]
26. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
27. Preparation of a new construct of human histone deacetylase 8 for the crystallization of enzyme-inhibitor complexes.
Porter NJ; Christianson DW
Methods Enzymol; 2019; 626():561-585. PubMed ID: 31606091
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
[TBL] [Abstract][Full Text] [Related]
29. Discovery of a fluorescent probe with HDAC6 selective inhibition.
Zhang Y; Yan J; Yao TP
Eur J Med Chem; 2017 Dec; 141():596-602. PubMed ID: 29102179
[TBL] [Abstract][Full Text] [Related]
30. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
31. Vitamin K
Dawood M; Hegazy MF; Elbadawi M; Fleischer E; Klinger A; Bringmann G; Kuntner C; Shan L; Efferth T
Biochem Pharmacol; 2020 Oct; 180():114176. PubMed ID: 32721508
[TBL] [Abstract][Full Text] [Related]
32. Macrocyclic Octapeptide Binding and Inferences on Protein Substrate Binding to Histone Deacetylase 6.
Watson PR; Gupta S; Hosseinzadeh P; Brown BP; Baker D; Christianson DW
ACS Chem Biol; 2023 Apr; 18(4):959-968. PubMed ID: 37027789
[TBL] [Abstract][Full Text] [Related]
33. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
[TBL] [Abstract][Full Text] [Related]
34. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
[TBL] [Abstract][Full Text] [Related]
35. Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
Sharma C; Oh YJ; Park B; Lee S; Jeong CH; Lee S; Seo JH; Seo YH
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835389
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
[TBL] [Abstract][Full Text] [Related]
37. Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors.
Nong Y; Hou Y; Pu Y; Li S; Lan Y
SLAS Discov; 2021 Jun; 26(5):628-641. PubMed ID: 33783263
[TBL] [Abstract][Full Text] [Related]
38. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
[TBL] [Abstract][Full Text] [Related]
39. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
[TBL] [Abstract][Full Text] [Related]
40. Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.
Cellupica E; Caprini G; Cordella P; Cukier C; Fossati G; Marchini M; Rocchio I; Sandrone G; Vanoni MA; Vergani B; Źrubek K; Stevenazzi A; Steinkühler C
J Biol Chem; 2023 Jan; 299(1):102800. PubMed ID: 36528061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
